Hepatorenal Syndrome Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight's "Hepatorenal Syndrome Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of Hepatorenal Syndrome. The report presents historical and projected epidemiological data covering Total Incident Cases of Hepatorenal Syndrome further segmented by Type and Comorbidity. In addition to epidemiology, the market report encompasses various aspects related to the patient population.

Discover which therapies are expected to grab the Hepatorenal Syndrome Market Share @ Hepatorenal Syndrome Market Outlook- https://www.delveinsight.com/sample-request/hepatorenal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Hepatorenal Syndrome Market Report
• In January 2025, Noorik Pharmaceuticals announced a clinical trial is to test whether the administration of low doses of ambrisentan can help patients with Hepatorenal Syndrome and to determine if it is safe. Ambrisentan is a drug that is approved for the treatment of high blood pressure in the lungs at higher doses. This clinical trial will compare the safety and effects of ambrisentan to another drug called terlipressin, which is commonly used to treat patients with hepatorenal syndrome.
• During the Hepatorenal Syndrome analysis, it was found that Hepatorenal Syndrome develops in patients with advanced cirrhosis so they will usually have jaundice and other stigmata of chronic liver disease such as finger clubbing, palmar erythema, and spider naevi.
• It was found that approximately 40% of patients with cirrhosis and ascites develop Hepatorenal Syndrome during the natural history of their disease.
• During the analysis, it was observed that Hepatorenal Syndrome acute kidney injury (AKI) accounts for approximately 11% of AKI in hospitalized cirrhotic patients with refractory ascites and is associated with high mortality.
• It was observed that the cumulative probability of developing Hepatorenal Syndrome at 1 year is approximately 18% and at 5 years is approximately 39% in patients with decompensated liver disease.
• The epidemiology of Hepatorenal Syndrome is expected to change during the forecast period (2024-2034).
• The leading Hepatorenal Syndrome Companies such as Cumberland Pharmaceuticals, Mallinckrodt, Ferring Pharmaceuticals, Ocelot Bio Inc., Novartis, and others.
• Promising Hepatorenal Syndrome Pipeline Therapies such as Terlipressin, Ambrisentan, OCE-205, Ifetroban Injection, Midodrine and others.

Stay ahead in the Hepatorenal Syndrome Therapeutics Market with DelveInsight's Strategic Report @ Hepatorenal Syndrome Market Outlook- https://www.delveinsight.com/sample-request/hepatorenal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hepatorenal Syndrome Epidemiology Segmentation in the 7MM
• Total Incident Cases of Hepatorenal Syndrome
• Total Diagnosed Prevalent Cases of Hepatorenal Syndrome
• Type-specific Cases of Hepatorenal Syndrome

Download the report to understand which factors are driving Hepatorenal Syndrome Epidemiology trends @ Hepatorenal Syndrome Prevalence- https://www.delveinsight.com/sample-request/hepatorenal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Marketed Hepatorenal Syndrome Drugs
• TERLIVAZ (terlipressin): Mallinckrodt Pharmaceuticals
TERLIVAZ, developed by Mallinckrodt Pharmaceuticals, is a vasopressin receptor agonist indicated to improve kidney function in adults with Hepatorenal Syndrome with a rapid reduction in kidney function. TERLIVAZ is the first and only FDA-approved product indicated for the treatment of adults with Hepatorenal Syndrome involving a rapid reduction in kidney function. Terlipressin is recommended by the American Association for the Study of Liver Diseases (AASLD) guidance and the American College of Gastroenterology (ACG) guidelines.

Hepatorenal Syndrome Emerging Drugs
• Ambrisentan: Noorik Biopharmaceuticals
Ambrisentan (N-003), an endothelin-A-receptor-antagonist is being developed by Noorik Biopharmaceuticals for the treatment of portal hypertension and associated hepatorenal syndrome with functional acute renal failure in patients with liver cirrhosis and delayed graft function (DGF). Ambrisentan can block the effects of endothelin on both the ETA and ETB receptors. Currently, the drug is in Phase II of clinical development for the treatment of Hepatorenal Syndrome.

• OCE-205: Ocelot Bio
OCE-205 is a peptide therapeutic with a differentiated OCE-205 mechanism of action (MOA) designed to selectively target serious hemodynamic complications that are the result of liver fibrosis and portal hypertension in end-stage liver disease (ESLD). The first indication being explored for OCE-205 is Hepatorenal Syndrome-AKI. OCE-205's innovation emanates from its design as a mixed agonist-antagonist peptide selective for the vasopressin 1a (V1a) receptor with no vasopressin 2 (V2) receptor activity at therapeutic concentrations. Currently, the drug is in Phase II of clinical development for the treatment of Hepatorenal Syndrome-AKI.

To learn more about Hepatorenal Syndrome Treatment guidelines, visit @ Hepatorenal Syndrome Treatment Market Landscape- https://www.delveinsight.com/sample-request/hepatorenal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hepatorenal Syndrome Market Outlook
The report's outlook on the Hepatorenal Syndrome market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Hepatorenal Syndrome Clinical Trials, drugs, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Hepatorenal Syndrome drug and late-stage pipeline therapy.

Hepatorenal Syndrome Drugs Uptake
The drug chapter of the Hepatorenal Syndrome report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of Hepatorenal Syndrome clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Hepatorenal Syndrome.

Major Hepatorenal Syndrome Companies
Cumberland Pharmaceuticals, Mallinckrodt, Ferring Pharmaceuticals, Ocelot Bio Inc., Novartis, and others.

Learn more about the FDA-approved drugs for Hepatorenal Syndrome @ Drugs for Hepatorenal Syndrome Treatment- https://www.delveinsight.com/sample-request/hepatorenal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Hepatorenal Syndrome Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Hepatorenal Syndrome Companies- Cumberland Pharmaceuticals, Mallinckrodt, Ferring Pharmaceuticals, Ocelot Bio Inc., Novartis, and others
• Hepatorenal Syndrome Therapies- Terlipressin, Ambrisentan, OCE-205, Ifetroban Injection, Midodrine and others.
• Hepatorenal Syndrome Market Dynamics: Hepatorenal Syndrome Market Drivers and Barriers
• Hepatorenal Syndrome Market Access and Reimbursement, Unmet Needs and Future Perspectives, Hepatorenal Syndrome Clinical Trials

Discover more about Hepatorenal Syndrome Drugs in development @ Hepatorenal Syndrome Clinical Trials Assessment- https://www.delveinsight.com/sample-request/hepatorenal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1 Key Insights
2 Report Introduction
3 Hepatorenal Syndrome Market Overview at a Glance
4 Epidemiology and Market Methodology
5 Executive Summary
6 Hepatorenal Syndrome Key Events
7 Disease Background and Overview: Hepatorenal Syndrome
8 Epidemiology and Patient Population
9 Patient Journey
10 Marketed Therapies
11 Emerging Therapies
12 Hepatorenal Syndrome: Seven Major Market Analysis
13 Key Opinion Leaders' Views
14 Hepatorenal Syndrome Unmet Needs
15 SWOT Analysis
16 Hepatorenal Syndrome Market Access and Reimbursement
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight

List of Top Selling Market Research Reports in 2025

Pulmonary emphysema market- https://www.delveinsight.com/report-store/pulmonary-emphysema-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Vital sign monitors devices market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cardiac implantable electronic devices market- https://www.delveinsight.com/report-store/cardiac-implantable-electronic-devices-cieds-market
NK Cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-pipeline-insight
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Thrombectomy devices market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
HIP Replacement devices market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
LY3454738 drug insight- https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Sepsis market_ https://www.delveinsight.com/report-store/sepsis-market-insight
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Coronary stents market- https://www.delveinsight.com/report-store/stents-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/
India:- +91-9650213330

This release was published on openPR.